Cite
HARVARD Citation
de Bono, J. et al. (2021). Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. Lancet oncology. 22 (9), pp. 1250-1264. [Online].